Thursday, 21. October 2021 | 15:35 - 16:10


Program Entry

«Machine Learning Drug Design (MLDD) and SARS-CoV-2 Mpro...»

Title: «Machine Learning Drug Design (MLDD) and SARS-CoV-2 Mpro Inhibitor Discovery», Elisa Liberatore and Julien Hazemann, Idorsia Pharmaceuticals Ltd.

Machine Learning Drug Design (MLDD) is a data-driven, iterative, and highly collaborative way of designing new drug candidates. MLDD can integrate several ML models for multi-parameter optimisation and more traditional CADD approaches such as 3D docking or pharmacophore screening to identify the most promising among the generated virtual compounds. It is also an extremely modular approach, in which every step, from structure generation to filtering, can be adapted to the specific project needs. 
In this talk we will introduce Idorsia’s MLDD platform, focusing on its most challenging aspects, and we will present an application of MLDD to the quest for new SARS-CoV-2 Mpro inhibitors, a project in collaboration with TU-Dortmund. 



Elisa Liberatore and Julien Hazemann, Idorsia Pharmaceuticals Ltd., Hegenheimermattweg 91, 4123 Allschwil


Show full program of the AI & Digitalization Symposium, Oct 21, 2021

More interesting events

Saved in your Bookmarks

We use cookies on our website. Some of them are essential, while others help us to improve this website. We are grateful if you accept them. More info